evoclass
hospira produtos hospitalares ltda - antineoplasico
evoclass
wyeth indÚstria farmacÊutica ltda - antineoplasico
evomid
evolabis produtos farmacÊuticos ltda - antineoplasicos citotoxicos
evomid
wyeth indÚstria farmacÊutica ltda - antineoplasicos citotoxicos
evorubicin
evolabis produtos farmacÊuticos ltda - antibioticos antineoplasicos
evorubicin
hospira produtos hospitalares ltda - antibioticos antineoplasicos
oncodox
ucb biopharma ltda. - antineoplasico
zavedos
laboratÓrios pfizer ltda - antineoplasicos citotoxicos
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leucemia, mieloide - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.